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ABSTRACT
Objectives Cancer survival rates vary widely between 
European countries, with differences in timeliness of 
diagnosis thought to be one key reason. There is little 
evidence on the way in which different healthcare systems 
influence primary care practitioners’ (PCPs) referral 
decisions in patients who could have cancer.
This study aimed to explore PCPs’ diagnostic actions 
(whether or not they perform a key diagnostic test and/or 
refer to a specialist) in patients with symptoms that could 
be due to cancer and how they vary across European 
countries.
Design A primary care survey. PCPs were given vignettes 
describing patients with symptoms that could indicate 
cancer and asked how they would manage these patients. 
The likelihood of taking immediate diagnostic action (a 
diagnostic test and/or referral) in the different participating 
countries was analysed. Comparisons between the 
likelihood of taking immediate diagnostic action and 
physician characteristics were calculated.
Setting Centres in 20 European countries with widely 
varying cancer survival rates.
Participants A total of 2086 PCPs answered the survey 
question, with a median of 72 PCPs per country.
Results PCPs’ likelihood of immediate diagnostic action 
at the first consultation varied from 50% to 82% between 
countries. PCPs who were more experienced were more 
likely to take immediate diagnostic action than their peers.
Conclusion When given vignettes of patients with a low 
but significant possibility of cancer, more than half of PCPs 
across Europe would take diagnostic action, most often by 
ordering diagnostic tests. However, there are substantial 
between- country variations.
BACKGROUND
Cancer survival rates vary widely across 
Europe.1 The fifth cycle of the European 
Cancer Registry- based Study on Survival and 
Care of Cancer Patients shows that national 
1- year relative survival rates for all cancer 
sites vary from 58.2% to 81.1%,2 but there is 
no evidence on how much of this variation 
is attributable to infrastructure as opposed 
to individual physician’s clinical practice. 
Comparison of European 1- year and 5- year 
relative cancer survival rates2–5 shows that some 
countries have higher survival rates from most 
cancers (including Belgium, France, Sweden 
and Switzerland), while others have consis-
tently lower survival (including Bulgaria, 
Croatia, Poland and Scotland). This suggests 
that an improvement in cancer awareness 
Strengths and limitations of this study
 ► Recruitment of primary care practitioners (PCPs) 
from 20 European countries, 4 countries from each 
of the Northern, Southern, Eastern, Western and 
Central European geographical areas, provided 
variation in geography, health systems and levels of 
healthcare spending.
 ► The questionnaire was carefully developed and pi-
loted by general practitioners and other PCPs, and 
therefore grounded in their clinical experience.
 ► While the response rate varied between countries 
and was low, it was comparable to that of other 
equivalent surveys of primary care doctors.
 ► There was only one survey round, and follow- up 
rounds may have given more information about how 
PCPs’ decision- making changes as clinical cases 
evolve.
 ► Most samples were taken from each local lead’s 
own localities, and these may not have been repre-
sentative of their nations as a whole.
by copyright.
 on N
ovem
ber 4, 2020 at U
niversitaetsbibliothek B
ern. P
rotected
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-035678 on 31 O
ctober 2020. D
ow
nloaded from
 
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
7
8
0
6
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
2 Harris M, et al. BMJ Open 2020;10:e035678. doi:10.1136/bmjopen-2019-035678
Open access 
and early detection in relatively poorly performing coun-
tries could reduce the survival gap.4 While recent cancer 
survival rates show improvement in most countries,5 the 
between- country differences remain.6 However, this is not 
inevitable: Denmark’s considerable efforts to improve 
early detection rates7 have resulted in a narrowing of the 
gap between its own relatively poor cancer survival rates 
and those of its better performing Nordic neighbours.8 
There has been a call for studies that compare practice 
between well and poorly performing countries, to help 
gain an understanding of how these disparities may be 
remedied.5
Although 1- year and 5- year relative survival can be 
affected by overdiagnosis and lead- time biases,9 10 poorer 
1- year survival in some countries is thought to be rooted 
in diagnostic delay11 12 and more advanced disease at 
diagnosis.13 14 The more advanced a cancer is, the more 
difficult it is to treat it successfully15 and, for many but 
not all cancers, disease stage at diagnosis is associated 
with survival.16 17 There is considerable evidence that 
longer time to diagnosis and treatment increases cancer 
mortality.18 19 Timely diagnosis of cancer is, therefore, 
a cornerstone of health policy throughout Europe.20 
However, there is a substantial challenge in deciding 
where and how to achieve this,21 as it is uncertain whether 
late diagnosis is due to patients with cancer presenting 
later, not being referred quickly enough from primary 
care, or whether they are inefficiently investigated, 
diagnosed and treated in secondary care.15 This may 
be a particular issue where patients with cancer present 
without ‘red- flag’ symptoms, as how the primary care 
practitioner (PCP) acts will depend to a large extent on 
local health service organisation.22 Balanced with a desire 
for more timely diagnosis of cancer is the need to avoid 
increased healthcare costs as well as to minimise overdi-
agnosis and overtreatment, though these latter concerns 
are particularly related to cancer screening.23–25
There is little evidence on how different healthcare 
systems influence PCPs’ referral decisions.21 However, a 
large variety of non- clinical factors affect these referral 
Table 1 Number of respondents per country, response rates, mean national cancer survival rates for the four cancers of 
interest
Number of 
respondents (% of 
all respondents)
Number of 
PCPs invited
Response 
rate (%)
1- year relative 
cancer survival* 
(%)
5- year relative 
cancer 
survival* (%)
Respondents per country (in alphabetical order)
  Bulgaria 59 (2.8) 90 65.6 59.6 38.4
  Croatia 67 (3.2) 292 22.9 63.7 44.7
  Denmark 107 (5.1) 400 26.8 69.0 45.4
  England 65 (3.1) 300 21.7 65.2 42.7
  Finland 65 (3.1) 178 36.5 73.2 50.3
  France 59 (2.8) 550 10.7 74.9 49.8
  Germany 103 (4.9) 242 42.6 73.5 50.3
  Greece 68 (3.3) 318 21.4 Data not available
  Israel 75 (3.6) 339 22.1 79.2† 58.3†
  Italy 63 (3.0) 200 31.5 72.9 49.4
  Netherlands 113 (5.4) 1601 7.1 72.0 49.1
  Norway 90 (4.3) 500 18.0 72.8 49.9
  Poland 152 (7.3) 422 36.0 65.8 41.5
  Portugal 65 (3.1) 227 28.6 71.0 48.2
  Romania 177 (8.5) Not known Data not available
  Scotland 65 (3.1) 350 18.6 66.5 43.7
  Slovenia 104 (5.0) 352 29.5 69.5 44.8
  Spain 446 (21.4) Not known 70.3 46.8
  Sweden 79 (3.8) 400 19.8 75.9 51.5
  Switzerland 64 (3.1) 100 64.0 75.7 50.2
  Total 2086 (100)
*Calculated using International Cancer Survival Standards (ICSS).
†Calculated from data provided by B. Silverman, Israel Ministry of Health (personal communication, 7 September 2017) and Y. Schonmann, 
London School of Hygiene & Tropical Medicine (personal communication, 7 September 2018).
PCPs, primary care practitioners.
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decisions.22 These include the extent of gatekeeping, 
funding systems, access to special investigations, concerns 
over litigation and barriers to accessing specialist advice 
as well as the availability of fast- track programmes for 
suspected cancer. Whether the responsibility for early 
detection of cancer is principally in primary or secondary 
care varies between countries. The International Cancer 
Benchmarking Partnership (ICBP)26 examined the 
differences in cancer awareness and beliefs between 
six countries with comparable wealth in an attempt to 
explain differences in cancer survival.27 It found a posi-
tive association between national cancer survival rates 
and the readiness of PCPs in those countries to investi-
gate potential cancer symptoms.28 However, there has not 
yet been an investigation of how PCPs’ diagnostic actions 
(a key diagnostic test and/or referral to a specialist) 
with respect to potential cancer symptoms vary across 
Europe, among countries with a wide range of socioeco-
nomic development, healthcare systems and healthcare 
spending. Also, while there is evidence that PCP gender 
can affect specialist referral rates29 30 as may the extent of 
their professional experience30 and whether or not they 
work in rural areas,31 32 this has not been assessed with 
regards to referrals for patients who could have cancer.
We therefore aimed to explore how the diagnostic 
action rates of PCPs for patients with symptoms that could 
be due to four types of cancers (lung, ovarian, breast and 
colorectal) compared across European countries and to 
explore the effect of PCPs’ demographics on their diag-
nostic action rates for these cancers.
METHODS
Design
We provided clinical vignettes to PCPs from 20 Euro-
pean countries with markedly different socioeco-
nomic and healthcare systems. The vignettes described 
patients presenting with symptoms that could indicate 
cancer. Recruitment started in November 2015 and was 
completed at the end of 2016.
Outcome measures
The primary outcome was a comparison of PCPs’ imme-
diate diagnostic action rates (a key diagnostic test and/
or referral to a specialist) for patients with symptoms that 
could be due to cancer across the participating European 
countries.
The secondary outcome was an exploratory analysis to 
investigate the relationship between PCPs’ demographics 
and their diagnostic action rates.
Study population
The Örenäs Research Group (ÖRG) is a European 
collaborative of primary care researchers, formed in 2013 
to study the factors influencing national variations in the 
early diagnosis of cancer in primary care. The research 
was conducted in 25 ÖRG centres in 20 countries across 
Europe: Bulgaria, Croatia, Denmark, England, Finland, 
France, Germany, Greece, Israel, Italy, Netherlands, 
Norway, Poland, Portugal, Romania, Scotland, Slovenia, 
Spain, Sweden and Switzerland. Medical doctors were 
eligible for the survey if they were working mainly in 
primary care. These doctors, here referred to collectively 
as ‘PCPs’, included general practitioners (GPs) and other 
doctors who had other specialist training but worked in 
the community and could be accessed directly by patients 
without referral.
Development of the questionnaire
We used clinical vignettes as they have been validated as 
a measure of clinical practice.33 34 Following a literature 
review, ÖRG investigators developed a questionnaire 
designed to elicit PCPs’ demographic information and 
their actions for patients who could have cancer. The 
questionnaire with five clinical vignettes (three new ones 
and two designed and validated by the ICBP35 and used 
with permission) was piloted by the ÖRG local leads in 
January 2015 to check validity. More information about 
this process is given elsewhere.36 No changes to the 
demographic questions were made. One of the vignettes 
Table 2 Demographic distributions of respondents
Number (%)
Gender
  Female 1274 (61.1)
  Male 790 (37.9)
  Not stated 22 (1.1)
Years since graduation
  <10 years 331 (15.5)
  10–19 years 553 (26.9)
  20–29 years 609 (29.2)
  30–39 years 499 (23.9)
  40 years or over 76 (3.6)
  Not stated 18 (0.9)
Site of practice
  Urban 1238 (59.3)
  Rural 485 (23.3)
  Remote or island 56 (2.7)
  Mixed 295 (14.1)
  Not stated 12 (0.6)
Number of doctors in practice
  1 286 (13.7)
  2 233 (11.2)
  3 226 (10.8)
  4–5 347 (16.6)
  6–7 259 (12.4)
  8–9 172 (8.2)
  10 or more 542 (26.0)
  Not stated 21 (1.0)
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was found to be invalid and was removed. The next 
version of the questionnaire, in English, was then piloted 
by 49 PCPs in 16 ÖRG member countries in July 2015. 
No changes to the questions were made following this 
second pilot.
ÖRG leads arranged for translations of the ques-
tionnaire into their local languages where these were 
not English, a total of 19 translations from the original 
English. Translation and validation by backtranslation 
were done in a standardised way37 and are described 
elsewhere.38
Description of the questionnaire
The questionnaire consisted of 47 items and was divided 
into four sections: (a) demographic questions (ques-
tions about years since graduation, gender, rural/urban 
location of practice and number of doctors working in 
the practice), (b) referral availability questions (ques-
tions about tests and specialist opinions that were either 
directly or indirectly available to the respondent), (c) 
four fictitious clinical vignettes and (d) 20 health system 
factor questions. The patients’ names in the vignettes 
were pseudonyms. Each of the vignettes provided infor-
mation on the patient’s presenting symptoms, previous 
medical history, medication, clinical findings and other 
relevant information. A factor analysis of the results of 
the survey section on the effect of health system factors is 
reported separately.39
The version of the questionnaire for PCPs in England, 
on which those for the other countries were based, is 
given in online supplemental appendix 1. We chose to 
make the survey anonymous, as this has been shown to 
improve the honesty of responses to questions that may 
be considered sensitive.40
The demographic questions were:
 ► How many years is it since you graduated as a doctor? 
Under 10 years/10–19 years/20–29 years/30–39 
years/40 years or over/I prefer not to say.
 ► Are you—female?/male?/I prefer not to say.
 ► What type of practice do you work in? Urban/rural/
island or remote/mixed.
 ► How many doctors work in your practice/health 
centre in total? 1/2/3/4–5/6–7/8–9/10 or more.
The vignettes were chosen to have a low but significant 
possibility of cancer:
1. A 62- year- old male smoker with chronic obstructive 
pulmonary disease and now a 2- week history of a pro-
ductive cough; positive predictive value (PPV) for lung 
cancer: 3.6%41 .
2. A 53- year- old woman with lower abdominal pain and 
abdominal distension; PPV for ovarian cancer: 3.1%42 .
3. A 35- year- old breastfeeding woman with an abnormal 
nipple discharge and eczematous changes around the 
nipple; PPV for breast cancer: 1.2%43 .
4. A 22- year- old man with coeliac disease who now has 
abdominal pain, rectal bleeding and diarrhoea; PPV 
for colorectal cancer: 3.4%.41
For each patient, a range of five possible management 
decisions was given, with an invitation to choose as many 
as needed:
 ► ‘I would write an appropriate prescription for the 
patient’.
 ► ‘I would arrange to see the patient again for follow- up 
and reassessment’.
 ► ‘I would not arrange formal follow- up, but would tell 
the patient under what circumstances she/he should 
see me again’.
 ► ‘I would organise an investigation at this consultation’.
 ► ‘I would refer the patient to a specialist at this 
consultation’.
Those who chose to investigate the patient were able 
to select from a range of possible diagnostic tests. The 
response of primary interest was a PCPs’ management 
choice that would be likely to identify a cancer as a cause 
of the patients’ symptoms, by either opting to request a 
significant diagnostic test or by referring to a specialist. 
The tests used in the analysis were: a plain chest X- ray 
or lung CT for the lung vignette; a tumour marker, diag-
nostic ultrasound or CT for the ovarian vignette; an 
ultrasound of the breast or mammography for the breast 
vignette; and diagnostic ultrasound, sigmoidoscopy, 
colonoscopy or CT colonography for the colorectal 
vignette.
Sample size
We aimed for a total sample size of at least 1000 PCPs, with 
at least 50 responses from each of the participating coun-
tries. There was a pragmatic decision to use this sample 
size, as some ÖRG local leads were unsure as to whether 
they would be able to recruit more than this number 
because, in their participating countries, PCPs had little 
experience of research using online surveys.
Recruitment of participants
Each ÖRG local lead was asked to email an invitation to 
take part in the survey to the PCPs in their local health 
district or jurisdiction and to recruit at least 50 partici-
pants. In six countries (Denmark, Norway, Portugal, 
Romania, Slovenia and Sweden), the invitation was 
distributed to a national sample. The recruitment email 
stated that the research aimed to identify which health 
system factors affect PCPs’ decisions to refer patients for 
further investigation. The possibility of cancer as being 
a cause of the vignette symptoms was not mentioned in 
either the recruitment email or the survey.
Distribution of the questionnaire
The questionnaire was designed using SurveyMonkey 
(SurveyMonkey, California, USA). Because of the study’s 
wide geographical coverage, online delivery of the ques-
tionnaire was used; this methodology has previously been 
successfully used in research involving cancer care profes-
sionals.44 45 Local leads were asked to send two follow- up 
reminders to encourage completion of the survey.
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Statistical analysis
Demographic questions and those relating to vignette 
decision- making were analysed using descriptive statistics. 
For each individual PCP, mean vignette decision- making 
rates were calculated from the four individual vignette 
responses. Merging the vignette data has face validity as 
we aimed to explore PCPs’ diagnostic actions in patients 
with symptoms that could be due to cancer, and the four 
cancers between them account for 37% of new cancer cases 
in Europe.46 Also, other authors have merged vignette data 
where the aim is to compare the action of different groups 
of healthcare professionals, as in this study, as opposed 
to comparing the effect of different vignettes on their 
action.47 48 For comparisons between countries, means, SDs 
and ranges were calculated. As it was considered that some 
PCPs would not organise a diagnostic test because they were 
referring to a specialist, and conversely some PCPs would 
not refer to a specialist because they were organising a diag-
nostic test, we used a composite measure of a decision to 
arrange a diagnostic test and/or refer to a specialist, that 
is, the likelihood of taking immediate diagnostic action 
for cancer. To compare these rates between countries, we 
fitted an analysis of variance (ANOVA) model to investi-
gate whether the differences were statistically significant. 
We fitted a mixed effects model, adjusted for country, to 
investigate the relationship between PCP demographics (as 
independent variables) and likelihood of immediate diag-
nostic action (the dependent, continuous variable). The 
Pearson correlation coefficient was calculated to examine 
correlations between PCPs’ likelihood of organising a diag-
nostic test and their likelihood of referring to a specialist, 
and between national response rates and PCPs’ likelihood 
of taking immediate diagnostic action in those countries. 
Calculations were performed using IBM SPSS V.25 and, for 
the mixed effects model, Stata SE V.15.1.
Patient and public involvement
There was no patient or public involvement in this study.
RESULTS
A total of 2086 PCPs completed the questionnaire. There 
was a median of 72 respondents per country, range 
59–446 (table 1).
The response rate for two countries was unknown. For 
the other 18 countries, the median response rate was 
24.8% (range 7.1%–65.6%). Participants’ demographic 
distributions are shown in table 2.
Organising a diagnostic test
The range of PCPs who stated that they would organise a 
diagnostic test at this first consultation varied from 35.6% 
to 80.1%, mean 54.1%, SD 11.2 (figure 1).
Referring the patient to a specialist
Across the participating countries, a mean of 33.6%, SD 
13.7, range 12.3%–64.7%, of PCPs decided to refer the 
patient to a specialist at the first consultation (figure 2).
Figure 1 Percentage of primary care practitioners in each 
country who would organise a diagnostic test.
Figure 2 Percentage of primary care practitioners in each 
country who would refer the patient to a specialist.
Figure 3 Percentage of primary care practitioners in each 
country who would organise an investigation and/or refer the 
patients to a specialist.
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Arranging a diagnostic test and/or referring the patient to a 
specialist
There was a strong correlation between PCPs’ likeli-
hood of organising a diagnostic test and their likelihood 
of referring to a specialist: r=0.77, p=<0.001. Across the 
surveyed countries, the proportion of PCPs who would 
take diagnostic action at this first consultation varied 
from 50.0% to 82.1%, mean 62.6%, SD 10.3 (figure 3). 
This variation was statistically significant (p≤0.001).
Overall, the likelihood of immediate diagnostic action 
varied across the four cases: lung vignette 54.8%, ovarian 
vignette 56.7%, breast vignette 58.1% and colorectal 
vignette 78.1%.
Although there was a wide variation in response rates 
across the countries, there was no significant linear rela-
tionship between national response rates and PCPs’ like-
lihood of taking immediate diagnostic action in those 
countries (r=0.4, p=0.055, figure 4).
Other PCP actions
A mean of 41.2%, SD 13.8, of PCPs indicated that 
they would issue a prescription to the patients in their 
vignettes, though the range across the 20 countries was 
wide (21.7%–73.3%). This is shown in figure 5.
Between 43.7% and 77.6% of PCPs would arrange to 
see the patients again, mean 61.8%, SD 9.1 (figure 6).
A smaller proportion, mean 12.9%, SD 7.9, range 
1.6%–28.8%, indicated that they would not arrange 
formal follow- up but would tell the patient under what 
circumstances they should return (figure 7).
Effect of PCP demographics on their likelihood of immediate 
diagnostic action
The results of a mixed effects model analysis indicated 
that the number of years since graduation was a significant 
predictor of likelihood of immediate diagnostic action 
(table 3): PCPs who had graduated within the previous 
10 years were significantly less likely to investigate or refer 
than those who had graduated longer ago. Neither PCP 
gender nor size of practice had a significant effect.
In the 12 countries with respondents who self- identified 
as working in remote or island practices, those PCPs were 
Figure 4 Association between national response rates and primary care practitioners’ likelihood of taking immediate 
diagnostic action.
Figure 5 Percentage of primary care practitioners in each 
country who would issue a prescription.
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significantly more likely to take immediate diagnostic 
action than their colleagues (71.4% vs 60.7%, p=0.021).
DISCUSSION
Principal findings
When faced with vignettes of patients with symptoms that 
could be due to cancer, PCPs’ stated actions varied mark-
edly across 20 European countries. In all the participating 
countries, at least half of PCPs would have taken imme-
diate diagnostic action (either organised a key diagnostic 
test or referred the patient to a specialist or both).
PCPs who were more likely to arrange a diagnostic test 
were also more likely to refer their patients to a specialist 
at the same time. PCPs who had graduated more recently 
were less likely to take diagnostic action in these vignettes 
than their more experienced peers, and PCPs working in 
more remote locations were more likely to take diagnostic 
action than their colleagues in other localities.
Strengths and limitations of this study
One of the strengths of our study is the wide spectrum 
of participating centres, with four countries from each of 
the Central, Eastern, Northern, Southern and Western 
European geographical areas, providing variation in 
geography, socioeconomic and health systems and levels 
of healthcare spending. It included the views of PCPs 
who are not usually involved in research. The question-
naire was carefully developed and piloted by GPs and 
other PCPs, and therefore grounded in their clinical 
experience. We used clinical vignettes, which have been 
shown to be effective for cross- national studies.45 49 There 
is evidence that responses to vignettes in surveys corre-
spond well to clinical practice,28 and such surveys have 
previously been used to study primary care investigation 
preferences in patients who could have cancer.34
While vignette studies on mixed physician populations 
can achieve high response rates,45 49 low survey response 
rates are common in primary care35 36 and are known 
to vary between countries. However, those in our study 
compared favourably with those of a recent ICBP survey, in 
which response rates varied from 5.5% to 45.6%.50 There 
may be non- response bias, as those who did not complete 
the questionnaire may be systematically different from 
those who participated.
Most samples were taken from the local lead’s own 
localities, and these may not have been representative of 
Figure 6 Percentage of primary care practitioners in each 
country who would arrange to see the patients again.
Figure 7 Percentage of primary care practitioners in each 
country who would not arrange formal follow- up.
Table 3 Mixed effects model to investigate the relationship 
between PCP demographics and likelihood of immediate 
diagnostic action, adjusted for country
Demographic 
factor
Margin (95% 
confidence interval) Standard error
PCP gender
  Female 63.6 (58.9 to 68.3) 2.4
  Male 62.7 (57.9 to 67.6) 2.5
Years since graduation
  Less than 10 56.1 (50.5 to 61.6) 2.8
  10–19 64.3 (59.2 to 69.3) 2.6
  20–29 63.6 (58.5 to 68.6) 2.6
  30–39 66.1 (61.0 to 71.3) 2.6
  40 or over 66.3 (58.1 to 74.6) 4.2
Number of doctors in PCP’s practice
  1 64.8 (59.0 to 70.6) 3.0
  2 64.6 (58.6 to 70.5) 3.0
  3 62.4 (56.4 to 68.3) 3.0
  4–5 63.3 (57.8 to 68.7) 2.8
  6–7 60.8 (55.1 to 66.6) 2.9
  8–9 61.3 (54.9 to 67.7) 3.3
  10 or more 63.9 (58.4 to 69.3) 2.8
PCP, primary care practitioner.
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their nations as a whole.51 The recruitment method used 
in this study resulted in variable response rates, leading 
to a risk of non- response bias.52 However, the goal of 
50 survey participants per country and more than 1000 
respondents in total was achieved. There was a trend to 
a relationship between national response rates and like-
lihood of taking immediate diagnostic action, and while 
this did not reach significance, it may have influenced the 
findings.
We have no data on non- responders as the survey was 
anonymous. However, the respondent anonymity might 
have reduced the risk of social desirability bias. While 
respondents gave us some demographic data, in many 
participating countries there were no equivalent national 
data on PCP demographics. This, and the low response 
rates in some countries, means that we were unable to be 
sure how representative their results were of their wider 
PCP populations. The varying response rates may be due 
to differences in how the local study leads selected PCPs 
for the study and national variations in PCPs’ willingness 
to take part in online survey research.
It is possible that the PCPs with the most interest in diag-
nostic decision- making were the most likely to respond. 
Our respondents were only able to select their manage-
ment decisions from the options that we gave them; this 
means they might have selected an option that they would 
not have thought of without prompting, which may have 
affected the diagnostic testing and referral rates. There 
was only one survey round, and follow- up rounds may 
have given more information about how PCPs’ decision- 
making changes as clinical cases evolve.
Interpretation of the results
Diagnostic testing and referral rates for these vignettes 
differed widely between participating countries. However, 
the response rates were low in most of the countries 
surveyed, so the results should be interpreted with caution. 
Whereas we might expect that referring a patient would 
result in PCPs being less likely to organise a diagnostic 
test on their patient and vice versa, this was not confirmed 
in the survey: the more likely PCPs were to refer a patient, 
the more likely they were to organise a diagnostic test at 
the same time. The reasons for this are unclear, but it 
may be that PCPs who are more worried about patients 
with unexplained symptoms are more likely to take all the 
measures available to help them make a diagnosis.
While we found that PCPs working in remote locations 
were more likely to take immediate diagnostic action, this 
may be due to confounding, as doctors with young fami-
lies have been found to be less likely to work rurally.53
Comparison with the existing literature
While our study shows a link between PCP diagnostic 
actions and both practice location and duration of PCP 
experience, an ICBP study found no health system char-
acteristics that explained their findings.28 However, the 
ICBP study only studied six, relatively wealthy, countries 
(Australia, Canada, Denmark, Norway, Sweden and the 
UK). Another study found a lower likelihood of diag-
nostic action for PCPs working in larger practices.54 Our 
evidence that PCPs working in more remote locations were 
more likely to take diagnostic action for these vignettes 
links across to evidence that such remote living is asso-
ciated with more rapid cancer diagnosis and treatment 
following GP referral.55 While our data show higher diag-
nostic action rates in PCPs with more years since gradua-
tion, the opposite was found in a Finnish study,30 and no 
difference was found in a UK study.56 However, those two 
studies did not specifically study referrals for suspected 
cancer: it may be that experienced PCPs are more likely 
to recognise symptoms that suggest a possibility of cancer, 
even in the absence of ‘red- flag’ symptoms, because they 
are more likely to have previously seen patients with those 
symptoms who were subsequently found to have a serious 
diagnosis.
The extent to which respondents were gatekeepers, 
and needed to authorise their patients’ access to specialist 
care and diagnostic tests,57 may have been a factor in 
their diagnostic actions. There has been a suggestion that 
stronger gatekeeper systems are linked with lower 1- year 
relative cancer survival than non- gatekeeper systems,58 
possibly because gatekeeping can result in cost and 
resource decisions that reduce the likelihood of early 
referral.59 However, there are important variations in the 
level of gatekeeping between countries, with no simple 
binary model as to whether or not a country has a ‘GP- as- 
gatekeeper’ system, and a European study found no 
association between cancer survival and a probability of 
presentation to a GP.36
Implications for research and practice
This study has shown considerable national variation in 
PCPs’ actions when faced with patients who have a low but 
significant risk of cancer, and the reasons for this need 
to be investigated. While it might be expected that PCPs 
who are more likely to arrange a diagnostic test would 
be less likely to refer their patient in the same consulta-
tion, we found the opposite was the case, and research is 
needed to explain this.
CONCLUSION
When given vignettes of patients with a low but signifi-
cant possibility of cancer, more than half of PCPs across 
Europe would take diagnostic action (a key diagnostic test 
and/or referral to a specialist), most often by ordering 
diagnostic tests. However, there are substantial between- 
country differences.
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